Microtubule stabilising peptides rescue tau phenotypes in-vivo by Quraishe, Shmma et al.
1Scientific RepoRts | 6:38224 | DOI: 10.1038/srep38224
www.nature.com/scientificreports
Microtubule stabilising peptides 
rescue tau phenotypes in-vivo
Shmma Quraishe, Megan Sealey, Louise Cranfield & Amritpal Mudher
The microtubule cytoskeleton is a highly dynamic, filamentous network underpinning cellular structure 
and function. In Alzheimer’s disease, the microtubule cytoskeleton is compromised, leading to neuronal 
dysfunction and eventually cell death. There are currently no disease-modifying therapies to slow down 
or halt disease progression. However, microtubule stabilisation is a promising therapeutic strategy 
that is being explored. We previously investigated the disease-modifying potential of a microtubule-
stabilising peptide NAP (NAPVSIPQ) in a well-established Drosophila model of tauopathy characterised 
by microtubule breakdown and axonal transport deficits. NAP prevented as well as reversed these 
phenotypes even after they had become established. In this study, we investigate the neuroprotective 
capabilities of an analogous peptide SAL (SALLRSIPA). We found that SAL mimicked NAP’s protective 
effects, by preventing axonal transport disruption and improving behavioural deficits, suggesting both 
NAP and SAL may act via a common mechanism. Both peptides contain a putative ‘SIP’ (Ser-Ile-Pro) 
domain that is important for interactions with microtubule end-binding proteins. Our data suggests 
this domain may be central to the microtubule stabilising function of both peptides and the mechanism 
by which they rescue phenotypes in this model of tauopathy. Our observations support microtubule 
stabilisation as a promising disease-modifying therapeutic strategy for tauopathies like Alzheimer’s 
disease.
Alzheimer’s disease (AD) is the commonest cause of dementia in the elderly. It is characterised by progressive 
cognitive decline associated with neuronal dysfunction and death. Extracellular plaques made up of Aβ peptide 
and intraneuronal filaments/tangles composed of abnormal, highly phosphorylated forms of tau, neuropatholog-
ically define AD. Though this disease was first described over 100 years ago, disease-modifying therapies are still 
elusive and AD is on the rise. It is estimated that 65.7 million people worldwide will be living with dementia by 
20301. Clearly, there is an urgent, unmet need for disease-modifying therapies to treat AD2,3.
Tau is a microtubule binding protein that is important for the assembly, maintenance and stability of micro-
tubules (MT). Hyper-phosphorylation of tau, as found in AD, decreases its affinity for tubulin, compromising its 
ability to stabilise the MTs and thus disrupting cytoskeletal integrity and axonal transport4–6. These phospho-tau 
mediated phenotypes are evident in many in-vivo models of tauopathy7–10 including our own Drosophila model 
in which a wild-type, highly phosphorylated isoform of human tau (htau0N3R) is expressed11.
Drosophila is an established model system for analysing the cellular and molecular mechanisms that under-
lie a variety of neurodegenerative diseases, particularly tau-associated diseases12,13. Htau0N3R-expression in this 
model causes neuronal dysfunction, characterised by MT destabilisation6, axonal transport disruption11, syn-
aptic defects12 and behavioural impairments11. This model has been used to explore the effectiveness of disease‐
modifying interventions to either reduce tau phosphorylation or enhance MT stabilisation6,14. Treatment with 
NAP (NAPVSIPQ also known as ‘davunetide’), a small octapeptide derived from activity dependent neuropro-
tective protein (ADNP)15 effectively restores MT integrity14,16 and protects MT-dependent axonal transport in 
both rodent17 and Drosophila14 models of disease. Moreover, in the Drosophila model, NAP-mediated protection 
against htau0N3R phenotypes spans cellular and molecular dysfunction through to behavioural defects in-vivo14.
NAP is reported to modulate MT dynamics in a fashion similar to MT plus-end tracking proteins 
(+TIPS)18. +TIPS target the dynamic ends of MTs, catalysing immediate changes in MT stability, directionality 
and growth19,20. However, the majority of +TIPs do not interact directly with the MT plus-end and/or MT lat-
tice. Instead, this interaction occurs through end-binding proteins (EBs), which recognise and bind conserved 
Ser-x-Ile-Pro (SxIP) polypeptide motifs within +TIPs21. In addition to the classical ‘SxIP’ motif, ‘SIP’ and ‘IP’ 
sequences are also reported to mediate EB interaction with its binding partners22. NAP contains a ‘SIP’ motif 
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within its amino acid sequence (NAPVSIPQ). It interacts in-vitro18 with both EB1, a key regulator of MT dynam-
ics and polymerisation23,24 and EB3 a central component in dendritic spine formation25. Silencing of either EB1 or 
EB3 abolishes NAP’s protective activity in PC12 cells. Furthermore, silencing of EB3 in primary cortical neurons 
inhibits NAP-mediated dendritic spine formation18. A novel NAP analogue, SKIP, is reported to bind NAP and 
enhance axonal transport in ADNP-deficient mice26. It is therefore conceivable that NAP restores MT integrity 
and function in our Drosophila model of tauopathy by interacting with EB’s via its SIP domain. The data presented 
here tests this hypothesis by exploring the MT stabilising potential of another analogous peptide called SAL 
(SALLRSIPA also termed ADNF-9), which also contains a SIP domain. SAL is derived from the glial precursor 
protein, activity dependent neurotrophic factor (ADNF). It exhibits similar neuroprotective capabilities to NAP 
in numerous animal and cell models of injury and disease27–31.
In this study we investigated whether SAL, like NAP could also protect against htau0N3R-mediated neuronal 
dysfunction in our Drosophila model of tauopathy. The phenotypes that arise in this model occur as a direct or 
indirect consequence of MT breakdown. This model was therefore ideally suited to test SAL’s ability to modulate 
MT integrity and thus determine the importance of the SIP domain in MT stabilising therapeutic approaches.
Results
SAL prevents htau0N3R-mediated locomotor impairment. Expression of htau0N3R within motor neu-
rons of Drosophila manifests in a number of distinct phenotypes including crawling defects in larvae11. Larvae 
expressing htau0N3R exhibit a restricted and non-continuous crawling behaviour indicative of impaired neuronal 
function14,32. Using the image-tracking software Ethovision, crawling parameters were quantified including veloc-
ity, meander (turning rate per distance travelled) and angular velocity (turning rate per time elapsed). Meander and 
angular velocity are presented on a negative measurement scale in Ethovision. As previously shown14, 2.5 μg/ml 
NAP treatment significantly improved velocity (Fig. 1a, red bar, p = 0.0003, n = 14) compared to untreated 
htau0N3R-expressing larvae (Fig. 1a, black bar, n = 39). Meander and angular velocity were also significantly improved 
in NAP-treated larvae (Fig. 1b, red bar, p = 0.017, n = 12 and Fig. 1c, red bar, p = 0.0426, n = 12, respectively) 
compared to untreated htau0N3R-expressing larvae (Fig. 1b and c, black bar, n = 44 and 39, respectively). Larvae 
treated with SAL displayed a dose dependent improvement in all parameters tested. Treatment with 1.25 μg/ml 
and 2.5 μg/ml of SAL (Fig. 1a, pale green bar, n = 16 and light green bar, n = 39, respectively) did not improve 
velocity compared to untreated htau0N3R-expressing larvae (Fig. 1a, black bar, n = 39). However, 5 μg/ml SAL 
(Fig. 1a, green bar, p = 0.0001, n = 29) and 10 μg/ml SAL (Fig. 1a, dark green bar, p = <0.0001, n = 40) significantly 
improved velocity compared to untreated htau0N3R larvae (Fig. 1a, black bar, n = 39). Meander of htau0N3R-ex-
pressing larvae treated with 1.25 μg/ml and 2.5 μg/ml of SAL (Fig. 1b, pale green bar, n = 17 and light green 
bar, n = 40, respectively) did not improve compared to untreated htau0N3R-expressing larvae (Fig. 1b, black bar, 
n = 44). However, 5 μg/ml SAL (Fig. 1b, green bar, p = 0.0061, n = 31) and 10 μg/ml SAL (Fig. 1b, dark green 
bar, p = 0.0022, n = 49) significantly improved meander compared to untreated htau0N3R larvae (Fig. 1b, black bar, 
n = 44). Similar to the results for the previous crawling parameters assessed, angular velocity of htau0N3R-ex-
pressing larvae treated with 1.25 μg/ml and 2.5 μg/ml of SAL (Fig. 1c, pale green bar, n = 17 and light green 
bar, n = 38, respectively) did not improve compared to untreated htau0N3R-expressing larvae (Fig. 1c, black bar, 
n = 39). However, as also demonstrated for velocity and meander, 5 μg/ml SAL (Fig. 1c, green bar, p = 0.0044, 
n = 31) and 10 μg/ml SAL (Fig. 1c, dark green bar, p = 0.0165, n = 46) significantly improved angular velocity 
compared to untreated htau0N3R larvae (Fig. 1b, black bar, n = 39). Treatment with SAL (2.5 μg/ml and 10 μg/ml) 
did not alter the crawling performance of controls compared to untreated controls (Supplementary Figure 1b–d). 
Data were analysed by unpaired Student’s two-tailed t-test.
SAL prevents htau0N3R-mediated disruption of axonal transport. In this model, axonal transport is 
disrupted because of MT breakdown6,11. This can be visualised in-vivo and in real time through the expression of 
vesicular neuropeptide-Y-GFP (vGFP) in the motor neurons of living intact larvae11. Efficient axonal transport 
in untreated wild-type (wt) control larvae was evident by a homogeneous distribution of vGFP in peripheral 
nerves (Fig. 2a, n = 10). In htau0N3R-expressing larvae, large vGFP accumulates were distributed within the axons 
of peripheral nerves, illustrating profound axonal transport disruptions (Fig. 2b and e, black bar, p < 0.0001, 
n = 9). As previously demonstrated, 2.5 μg/ml of NAP prevented axonal transport deficits in htau0N3R-expressing 
larvae, thus restoring MT integrity (Fig. 2c and e, red bar, p < 0.0001, n = 5)14. Given that SAL improved crawling 
behaviour at higher doses (5 μg/ml and 10 μg/ml) compared to the more efficacious NAP (2.5 μg/ml), we assessed 
axonal transport deficits in htau0N3R-expressing larvae treated with 10 μg/ml of SAL. We found that 10 μg/ml 
of SAL prevented axonal transport deficits as effectively as 2.5 μg/ml of NAP (Fig. 2d and e, dark green bar, 
p < 0.0001, n = 9). Quantification of the total axonal area occupied by vGFP accumulates confirmed these results 
(Fig. 2e). Data were analysed by one-way ANOVA with Bonferroni’s correction.
SAL does not alter tau phosphorylation. The MT binding and stabilising ability of htau is reduced 
by hyper-phosphorylation5,6, leading to compromised cytoskeletal integrity. Reduction of tau phosphorylation 
through genetic and chemical manipulation is known to improve htau0N3R-mediated phenotypes6,33. However, 
we previously reported that NAP does not alter the phosphorylation status of htau0N3R and was conferring pro-
tection by another mechanism14. We therefore investigated whether SAL was preventing the emergence of the 
htau0N3R-mediated phenotypes by reducing tau phosphorylation or whether it too, was bypassing the patho-
genic phospho-htau0N3R protein. We examined a number of phospho-tau epitopes associated with AD in both 
SAL-treated and untreated htau0N3R-expressing 1–3 day old flies. Each phospho-tau antigen (intensity of signal, 
pixels/mm2) was normalised to total htau levels on the same blot. This enabled assessment of changes in the 
phosphorylation status of tau, independent of changes in total tau levels. The AT180 monoclonal antibody detects 
phosphorylation of tau at Thr231. This site is important for MT binding, and phosphorylation, as occurs in AD 
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at this site, inhibits binding of tau to MTs34. Htau0N3R-expressing flies treated with SAL at 5 or 10 μg/ml did not 
show changes in tau phosphorylation at the phospho-tau epitope detected by the AT180 antibody compared to 
untreated htau0N3R larvae (Fig. 3a, n = 5). The AT8 monoclonal antibody detects phosphorylation of tau at Ser202/
Thr205. Htau0N3R-expressing flies treated with SAL at 5 or 10 μg/ml did not show changes in tau phosphorylation 
at the phospho-tau epitope detected by the AT8 antibody compared to untreated htau0N3R larvae (Fig. 3b, n = 5). 
Another phospho-tau epitope, Ser396/Ser404, that is abnormally phosphorylated in AD can be detected by the 
PHF-1 antibody35. Similar to AT180 and AT8, htau0N3R-expressing flies treated with SAL at 5 or 10 μg/ml did not 
show changes in tau phosphorylation at the phospho-tau epitope detected by the PHF-1 antibody compared to 
Figure 1. SAL improves the locomotor phenotype in htau0N3R-expressing Drosophila larvae. Crawling 
performance (velocity, meander (turning rate per distance travelled) and angular velocity (turning rate per 
time elapsed)) was quantified using the tracking-software Ethovision. NAP treatment significantly improved all 
crawling parameters (a–c, red bar) compared to untreated htau0N3R-expressing larvae (a–c, black bar). A dose 
dependent improvement in all crawling parameters was observed in SAL-treated larvae. 5 μg/ml SAL (green 
bars) and 10 μg/ml SAL (dark green bars) significantly improved crawling performance: velocity (a), meander 
(b) and angular velocity (c) compared to untreated htau0N3R-expressing larvae (black bars). Data were analysed 
with an unpaired Students t-test. Error bars represent mean ± S.E.M., *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001 as determined by unpaired Student’s two-tailed t-test, n = wt (21–27), htau0N3R (39–44), 2.5 μg/
ml NAP (12–14), 1.25 μg/ml SAL (16–17), 2.5 μg/ml SAL (38–40), 5 μg/ml SAL (29–31) and  
10 μg/ml SAL (40–49).
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untreated htau0N3R larvae (Fig. 3c, n = 5). Total dtau and htau levels were not significantly different in SAL-treated 
compared to untreated htau0N3R-expressing flies (Fig. 3d and e). Actin was used as an additional protein loading 
control for all samples (Fig. 3d,e and Supplementary Figure 2). We did not include wt control animals in this anal-
ysis as they do not express htau0N3R (Supplementary Figure 1a). Wide view panels of all the blots are presented in 
Supplementary Figure 2. Data were analysed by one-way ANOVA with Bonferroni’s correction.
Discussion
In this study, we demonstrate that the neuroprotective peptide SAL (SALLRSIPA) provides protection 
against htau0N3R-mediated phenotypes as also demonstrated for an analogous neuroprotective peptide NAP 
(NAPVSIPQ), albeit at higher doses (5 and 10 μg/ml for SAL compared to 2.5 μg/ml for NAP). SAL significantly 
improved htau0N3R-mediated phenotypes in-vivo, including axonal transport disruption and behavioural defects. 
SAL was able to rescue htau0N3R phenotypes without altering phosphorylation at key disease-associated epitopes. 
These results are reminiscent of those observed with NAP-treatment in this model of tauopathy14. SAL is reported 
to exhibit a similar neuroprotective profile compared to NAP36,37. However, several studies have also shown that 
NAP is more efficacious than SAL15,29. This is consistent with our observations in the present study.
SAL and NAP – two neuroprotective peptides. SAL and NAP are short peptides derived from two 
secreted astroglial parent proteins, ADNF and ADNP (respectively)15,38,39. NAP and SAL were identified as the 
essential regions of their respective parent proteins for conferring neuroprotection39. In subsequent studies, SAL 
and NAP were found to protect against a variety of cellular insults including neurotoxic drugs such as NMDA40 
and ethanol28,41. They were also found to be protective in models of Alzheimer’s disease7,27,42,43, diabetic neuropa-
thy44, amylolateral sclerosis and ADNP induced tauopathy10,17,45. The molecular mechanism underpinning NAP’s 
neuroprotective ability is thought to occur by MT stabilisation46, which counters axonal transport defects14,17. It is 
conceivable that like NAP, SAL also has MT stabilising effects as it has been shown to displace NAP in an in-vitro 
MT binding assay47. SAL also promotes neurite outgrowth in rat hippocampal cultures, a function reliant on 
MT stabilisation and plasticity48. The data presented herein supports this further by showing that like NAP, SAL 
also protects against htau0N3R-mediated behavioral and axonal transport defects, which arise due to cytoskeletal 
destabilisation6,14. These htau0N3R-phenotypes could be attributed to neurodevelopmental effects given the drivers 
used in this study (D42- and Elav-Gal4) are not exclusively post-mitotic and motor-neuron specific49,50. D42-Gal4 
is expressed in all post-mitotic motor neurons and in some sensory neurons in the peripheral nervous system49. 
Elav-Gal4 is also expressed in post-mitotic neurons, but is transiently expressed in embryonic glial cells and neu-
roblasts50. Importantly, expression of htau0N3R with these drivers results in robust phenotypes, including MT dest-
abilisation and disrupted axonal transport within the motor neurons of Drosophila. We have previously shown 
rescue of htau0N3R-mediated axonal transport deficits after just 24 hours NAP treatment14. This implies that the 
protective effects of NAP and SAL target htau0N3R-phenotypes that arise in this model due to MT-associated 
neuronal dysfunction11. We previously demonstrated by EM that cytoskeletal integrity in wt (OreR) controls was 
unaffected by NAP treatment14. Unsurprisingly, no effect of NAP was evident in axonal transport or behavioural 
assays in these wt controls. In contrast, the same ultrastructural analysis showed a disrupted cytoskeleton, which 
was restored by NAP-treatment in htau0N3R-expressing animals14. Likewise, in the current study, wt controls 
treated with SAL did not show any statistically significant differences in locomotor performance compared to 
untreated controls, as illustrated in Supplementary Figure 1b–d. An important point to note is that wt strains such 
as OreR are more robust when compared to isogenised, Gal4/UAS strains which may be susceptible to Gal4 titra-
tions. It would have been ideal to confirm the tau-specific, neuroprotective effect of these peptides, by assessing 
Figure 2. SAL prevents axonal transport deficits in htau0N3R-expressing Drosophila larvae. Wild-type, 
control untreated larvae exhibited a homogeneous distribution of vGFP fluorescence in peripheral nerves 
indicative of an efficient axonal transport system (a). Htau0N3R larvae exhibited accumulation of vGFP, indicative 
of disrupted axonal transport (b). 2.5 μg/ml NAP prevented accumulation of vGFP in htau0N3R larval motor 
neurons (c). 10 μg/ml SAL also prevented accumulation of vGFP in htau0N3R larval motor neurons (d). The 
total area of axons (within a defined region) encompassed by vGFP accumulates was greater in htau0N3R larvae 
compared to controls. 2.5 μg/ml NAP and 10 μg/ml SAL reduced the area covered by vesicular accumulates back 
to control levels (e). Data were analysed by one-way ANOVA with Bonferroni’s correction. Error bars represent 
mean ± S.E.M., P**** < 0.0001; n = wt (10), htau0N3R (9), 2.5 μg/ml NAP (5), 10 μg/ml SAL (9). Scale bar: 10 μm.
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Figure 3. SAL does not alter total htau0N3R levels or phosphorylation at a number of sites relevant to AD. 
For each phospho-tau antigen, intensity of signal (pixels/mm2) was normalised to total tau levels. There was 
no significant change in the levels of the phospho-tau epitopes detected by AT180 (a), AT8 (b), and PHF-1 
(c) after treatment with 5 μg/ml SAL (green bars) and 10 μg/ml SAL (dark green bars) SAL. Total dtau levels 
were not altered by SAL treatment (d). Representative blots are shown (a-d). All lanes were run on the same 
gel. Data were analysed by one-way ANOVA with Bonferroni’s correction. Error bars represent mean ± S.E.M; 
n = htau0N3R (5), 5 μg/ml SAL (5), 10 μg/ml SAL (5).
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their impact on transgenic control lines with a UAS background (e.g. UAS-LacZ). However, our primary aim in 
this study was to determine if SAL-treatment significantly affected htau0N3R-phenotypes arising because of MT 
destabilisation. As such, treated and untreated Drosophila expressing htau0N3R were reared and tested alongside 
each other to minimise any titration and genetic artefacts. Interestingly, we found that axonal transport deficits 
could be prevented and efficient axonal transport maintained in htau0N3R-expressing animals at a comparable level 
to robust wt OreR control larvae.
Mode of action of SAL and NAP. Hyper-phosphorylated tau is considered to be the toxic species in 
tauopathies. It is believed to cause degeneration both due to loss of MT-binding function and accumulation of 
toxic tau aggregates51,52. Tau-centric disease-modifying strategies rescue tau phenotypes by reducing tau phos-
phorylation11,53, increasing MT stabilisation9,14,46,54 or reducing tau aggregation55. Our data imply neuroprotective 
effects independent of reductions in tau phosphorylation, but whether these peptides impact on tau aggregation 
remains to be determined. Interestingly, we have previously shown that inhibition of GSK-3β rescues tau pheno-
types and restores MT integrity, by reducing tau phosphorylation with a consequent increase in tau protein levels 
and insoluble granular tau oligomers56. In the present study, we did not observe any significant changes in total 
htau0N3R protein and phosphorylation levels after treatment with SAL and as demonstrated for NAP14. Previous 
findings from our lab, as well as other studies conducted in rodent and cell culture models of tauopathy, strongly 
suggest that NAP neuroprotects by fortification of MTs14,16–18,57.
In this study, we assessed the neuroprotective capabilities of both NAP and SAL peptides individually. SAL 
showed dose-dependent neuroprotective effects, consistent with our previous observations for NAP14. Other 
studies have also reported dose-dependent neuroprotective effects for both peptides29. In a rat model of choli-
notoxicity, NAP was more efficacious compared to SAL in cholinergic protection29. NAP has also been shown 
to be more effective then SAL in providing long term protection against loss of spatial memory in apolipopro-
tein E-deficient mice15 and AF64A-treated animals29. A combinatorial peptide approach would also have been 
interesting but is beyond the scope of the current study. However, previous studies have investigated the protec-
tive effects of combining both NAP and SAL. A few studies have shown that both peptides are more efficacious 
together, than either alone58–61. These peptides do not exhibit stereo-selectivity59. The more stable, all D-amino 
acid SAL (D-SAL) showed efficacy in-vivo and in-vitro models of disease30,31. In a model of fetal alcohol syndrome 
(FAS), administration of both D-NAP and D-SAL reduced fetal demise, however, no significant differences 
between combination and individual drug treatments were seen. In the same study, apolipoprotein E knockout 
mice treated with both D-NAP and D-SAL showed improved performance in the Morris water maze59. In another 
study, NAP alone was effective in preventing alcohol-induced fetal death, whereas SAL at the same dose was not 
protective. However, a combinatorial treatment with NAP and SAL was more effective in preventing growth 
restriction due to prenatal alcohol treatment60. These studies suggest a dose-dependent, synergistic effect rather 
than an additive effect. The differences reported in the literature and the differences in efficacious dose that we too 
observe may be attributable to the non-homologous amino acids either side of the SIP motif in the two peptides.
Interestingly, both peptides are derived from parent proteins that are secreted by glial cells in response to vas-
oactive intestinal peptide (VIP)15,38. VIP is expressed under conditions of stress and one of the early events that 
occurs during stress or insult mediated injury is a dynamic reorganisation of the cytoskeleton62. Both NAP and 
SAL (NAPVSIPQ and SALLRSIPA) contain a SIP motif63. The ‘SIP’ motif within NAP has been implicated in pro-
tection against ethanol and tetrodotoxin toxicity in cortical neurons40. Substitution of proline (P) with alanine (A) 
abolishes neuroprotection against oxidative stress (H2O2) in pheochromocytoma (PC12) cells64. Indeed, the SIP 
motif of NAP and SAL is essential for neuroprotection and interaction with key MT end-binding proteins EB1 
and EB3, promoting MT assembly and neuronal plasticity18,26. Collectively, our data and the studies discussed 
imply that SAL acts in a similar manner as NAP to confer neuroprotection. However, since the molecular mode of 
action of SAL has not been explored as comprehensively as that of NAP, this cannot be concluded unequivocally 
without further investigations.
The data presented here supports the use of SIP containing neuropeptides like NAP and SAL for protection 
against MT destabilisation such as that seen in tauopathies. Importantly, this work highlights MT stabilisation 
as a disease-modifying therapeutic strategy that holds great promise for tauopathies like AD where abnormal 
tau-mediated MT dysfunction is evident.
Methods
Drosophila genotypes and drug treatments. Transgenic expression of htau0N3R (y1w1118; P{UAS-
MAPT.A}59 A: Bloomington Stock Centre, stock no. 181) was directed to Drosophila melanogaster motor neurons 
using either D42-Gal4, or the D42-Gal4 driver fused to vesicular GFP-tagged neuropeptide-Y (D42-GAL4.UAS-
NPY:GFP) as previously described11. Pan-neural expression was established with the Elav-Gal4 driver. Female 
virgin flies homozygous for the D42 or Elav driver were crossed to male flies homozygous for htau0N3R under 
the UAS promoter (+;+; UAS-htau0N3R), or with Oregon-R (OreR) wt, control males. Stocks and transgenic 
crosses were maintained at 23 °C on a 12 h light/dark cycle. Flies were raised on basic food consisting of malt 
extract, maize meal, soya flour, agar, granulated sugar, yeast, and propionic acid. NAP (NAPVSIPQ) and SAL 
(SALLRSIPA) (L-isoforms synthesised by Peptide Protein Research Ltd, UK) were delivered to basic fly food at a 
final concentration of 2.5 μg/ml (NAP) and 1.25 μg/ml, 2.5 μg/ml, 5 μg/ml or 10 μg/ml (SAL). Late L3-stage larvae 
were selected for by size and wandering behaviour.
Larval locomotion assay. Larval locomotion analysis was conducted using a semi-quantitative assay as 
previously described32. Briefly, crawling behaviour was analysed on 1% agarose plates dyed with 0.1% w/v Alcian 
blue (Hopkin and Williams, UK). L3 larvae were positioned in the centre of each plate and allowed to acclimatise 
for 2 min prior to testing. Open field activity was recorded for 2 min (trial 1). This was further repeated for 2 
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more trials. Wherever possible, genotypes and treatments were randomised between adjacent plates. Videos of 
larval locomotion were analysed in Ethovision 3.0 software (Noldus) to determine velocity, angular velocity and 
meander.
In-vivo axonal transport analysis. All treatment groups were subjected to a 3–4 hour timed lay on apple 
juice agar plates. F1 eggs were transferred to either basic, NAP or SAL treated food. Larvae were left to develop 
to L3 wandering stage (day 5). Axonal transport analysis was conducted as previously described11,65. Briefly, L3 
larvae were anaesthetised in diethylether vapour for 15 min, immobilised on glass slides in 1% agarose ventral 
face up and mounted under coverslips. Peripheral nerves were analysed between the 2nd and 4th denticle bands. 
For total area acquisition, vGFP accumulates were imaged at x63 on an Axioplan2 Epifluorescence Microscope 
(Zeiss), and thresholded in Metamorph software (Molecular Devices, CA, USA).
Western blotting. 1–3 day old adult fly heads were homogenised in buffer (150 mM NaCl, 50 mM MES 
pH6.8, 1% triton-X, protease inhibitor cocktail and 1% SDS). For phospho-tau epitope detection, the following 
cocktail of phosphatase and kinase inhibitors was also added: 30 mM sodium fluoride, 20 mM sodium pyrophos-
phate, 40 mM 2-glycerophosphate, 3.5 mM sodium orthovanadate and 10 μM staurosporin. Samples were spun 
for 2 mins at 3,000 g; the supernatant was removed and heated for 5 mins at 95 °C in Laemmli buffer. Samples were 
subjected to standard 10% SDS-PAGE and transferred to Protran Nitrocellulose Membrane (Whatman, UK). 
Blots were probed with the following primary antibodies: anti-human tau (1:15,000, Dako, UK), anti-dtau (1:500, 
gifted by Prof. St. Johnston, University of Cambridge, UK), anti-actin (1:5000, Abcam, UK) and anti-phospho-tau: 
PHF-1 (1:2000, gifted by Dr. Peter Davies, Albert Einstein College of Medicine; Bronx, NY), AT180 (1:100, Source, 
Biosciences, UK), AT8 (1:800, Source, Biosciences, UK). Signal was detected using fluorescently-conjugated sec-
ondary antibodies; goat anti-mouse (Alexa-Fluor, Invitrogen, UK) and goat anti-rabbit (IRDye, Licor, UK), used 
at 1:20,000, and quantified with an Odyssey Infrared Imaging Scanner (LiCor) at 700 nm and 800 nm to give 
intensity values in pixels/mm2.
Statistics. Statistical analysis was carried out in Prism 5.0 (GraphPad, University of Southampton, 
Southampton, UK), using a T-test or one-way ANOVA with a post hoc Bonferroni’s Multiple Comparison Test. 
All values are reported as means ± S.E.M. P < 0.05 was considered significant.
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